Prevention of clofilium-induced torsade de pointes by prostaglandin E 2 does not involve ATP-dependent K+ channels

European Journal of Pharmacology

Volumn 472, Issue 3, 2003, Pages 189-196

  Farkas, András ^a   Coker, Susan J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

ATP dependent K+ channel; K + channel; Proarrhythmia; Prostaglandin E2; QT prolongation; Torsade de pointes

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA ADRENERGIC RECEPTOR; CLOFILIUM; GLIBENCLAMIDE; PENTOBARBITAL; POTASSIUM CHANNEL; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEVER; HEART LEFT VENTRICLE; INCIDENCE; INFLAMMATION; INFUSION; MALE; NONHUMAN; OPEN HEART SURGERY; PREMEDICATION; PRIORITY JOURNAL; RABBIT; TORSADE DES POINTES;

EID: 0142122881     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01910-1     Document Type: Article

References (29)

1. Batey A.J., Coker S.J. Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br. J. Pharmacol. 135:2002;1003-1012.
2. 2 may activate ATP sensitive potassium channels in the isolated rat heart. Cardiovasc. Res. 28:1994;901-905.
3. Buchanan L.V., Kabell G., Brunden M.N., Gibson J.K. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J. Cardiovasc. Pharmacol. 22:1993;540-549.
4. Carlsson L., Almgren O., Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J. Cardiovasc. Pharmacol. 16:1990;276-285.
5. Carlsson L., Abrahamsson C., Drews L., Duker G. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation. 85:1992;1491-1500.
6. Castle N.A. Selective inhibition of potassium currents in rat ventricle by clofilium and its tertiary homolog. J. Pharmacol. Exp. Ther. 257:1991;342-350.
7. 2 opens cardiac inward rectifier potassium channels: an explanation for prevention of torsade de pointes. Br. J. Pharmacol. 137:2002;. 22P.
8. 2α, prostacyclin, flurbiprofen and aspirin on arrhythmias resulting from coronary artery ligation in anaesthetized rats. Br. J. Pharmacol. 74:1981;155-159.
9. Crumb W.J., Wible B., Arnold D.J., Payne J.P., Brown A.M. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine-possible mechanism for terfenadine-associated cardiotoxicity. Mol. Pharmacol. 47:1995;181-190.
10. Daleau P., Lessard E., Groleau M.F., Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation. 91:1995;3010-3016.
11. Farkas A., Coker S.J. Limited induction of torsade de pointes by terikalant and erythromycin in an in vivo model. Eur. J. Pharmacol. 449:2002;143-153.
12. Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 103:2001;2004-2013.
13. Hondeghem L.M., Dujardin K., De Clerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc. Res. 50:2001;345-353.
14. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 349:1997;667-674.
15. Kowey P.R., Friehling T.D., O'Connor K.M., Wetstein L., Kelliher G.J. The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart. Am. Heart J. 110:1985;363-370.
16. + channel in guinea pig distal colonic crypts. Am. J. Physiol. Cell Physiol. 282:2002;C719-C735.
17. Li Q., Himmel H.M., Ravens U. Selectivity of class-III antiarrhythmic action of clofilium in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol. 27:1996;401-410.
18. + channel in human erythrocytes and alters cell volume and filterability. J. Biol. Chem. 271:1996;18651-18656.
19. + channel mutant probed by viral gene transfer in cardiomyocytes. J. Physiol. (London). 533:2001;127-133.
20. Mattioni T.A., Zheutlin T.A., Sarmiento J.J., Parker M., Lesch M., Kehoe R.F. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann. Intern. Med. 111:1989;574-580.
21. Monlun E., Pillet O., Cochard J.F., Garrigues J.C.F., Lebras M. Prolonged QT interval with halofantrine. Lancet. 341:1993;1541-1542.
22. Nosten F., Terkuile F.O., Luxemburger C., Woodrow C., Kyle D.E., Chongsuphajaisiddhi T., White N.J. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 341:1993;1054-1056.
23. Oberg K.C., Bauman J.L. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy. 15:1995;687-692.
24. 2 contracts vascular smooth muscle and inhibits potassium currents in vascular smooth muscle cells of rat tail artery. J. Pharmacol. Exp. Ther. 275:1995;710-719.
25. Rubart M., Pressler M.L., Pride H.P., Zipes D.P. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation. 88:1993;1832-1844.
26. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 354:1999;1625-1633.
27. Vos M.A., van Opstal J.M., Leunissen J.D., Verduyn S.C. Electrophysiologic parameters and predisposing factors in the generation of drug-induced torsade de pointes arrhythmias. Pharmacol. Ther. 92:2001;109-122.
28. Walker M.J.A., Curtis M.J., Hearse D.J., Campbell R.W.F., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J.B., Harron D.W.G., Higgins A.J., Julian D.G., Lab M.J., Manning A.S., Northover B.J., Parratt J.R., Riemersma R.A., Riva E., Russell D.C., Sheridan D.J., Winslow E., Woodward B. The Lambeth Conventions - Guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc. Res. 22:1988;447-455.
29. Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 269:1993;1532-1536.